Boehringer Ingelheim International Gmbh

Thomas Muenzel

Andreas Daiber

Maximilian Von Eynatten

Uli Christian Broedl

Odd-Erik Johansen

Bruce A Perkins

Nima Soleymanlou

Afshin Salsali

Gabriel Woojai Kim

Hans-Juergen Woerle

Eric Williams Mayoux

David Z I Cherney

Michael Mark

Thomas Klein

Klaus Dugi

David Zi Cherney

David Cherney

The present invention relates to methods for treating and/or preventing SIRS and/or sepsis comprising the administration of an effective amount of a certain DPP-4 inhibitor, as well as to the use of a certain DPP-4 inhibitor for treating and/or preventing a metabolic disease in a patient with or at risk of SIRS and/or sepsis.

Use of a DPP-4 inhibitor in SIRS and/or sepsis

The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.

Pharmaceutical composition, methods for treating and uses thereof

Growing community of inventors

Mainz, Germany

Thomas Muenzel